Boris K Tchounga1, Bo L Hønge, Serge P Eholie, Patrick A Coffie, Sanne Jespersen, Christian Wejse, François Dabis, Gottlieb S Geoffrey, Didier K Ekouevi. 1. aUniversité. Bordeaux, ISPED, Centre INSERM U1219-Epidémiologie-Biostatistique, Bordeaux bINSERM, ISPED, Centre INSERM U1219-Epidemiologie-Biostatistique, Bordeaux, France cProgramme PACCI, site de recherche ANRS, Abidjan, Côte d'Ivoire dBandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau eDepartment of Infectious Diseases fDepartment of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark gService des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d'Ivoire hDepartments of Medicine & Global Health, University of Washington, Seattle, Washington, USA iDépartement des Sciences Fondamentales et Santé Publique, Université de Lomé, Lomé, Togo. *See supplemental information for the list of the IeDEA West Africa collaboration members, http://links.lww.com/QAD/A970.
Abstract
OBJECTIVES: HIV-2-infected individuals usually initiate antiretroviral therapy (ART) at an advanced age compared with HIV-1 patients, with a potential impact on treatment outcomes. This study aimed to investigate the effect of sex and age on mortality and loss to follow-up (LTFU) among HIV-2-infected individuals initiating ART. METHODS: Analyses were conducted using the database of the International Epidemiological Databases to Evaluate AIDS's collaboration in West Africa. LTFU was considered if the interval between the last visit and the closing date for this analysis was more than 180 days. Probability of death and LTFU were estimated with Kaplan-Meier methods. A Cox regression model was used to identify factors associated with death and LTFU over the first 24 months on ART. RESULTS: A total of 1825 HIV-2-infected individuals, including 60% women were considered for this analysis. The median age, baseline CD4 cell count, and follow-up duration were 45 years [interquartile range (IQR; 38-52)], 185 cells/μl [IQR (95-297)], and 28.8 months [IQR (9.8-58.9)], respectively. Over the first 24 months, the mortality rate was 5.2/100 person-years of observation [95% confidence interval (CI; 4.4-6.1)] and 469 (25.7%) were LTFU. Male sex [hazard ratio (HR) = 1.9; 95% CI (1.4; 2.8)], baseline CD4 cell count less than 100 cell/μl [HR = 4.4 95% CI (1.7; 11.1); ref at least 350 cell/μl], haemoglobin 7.5-10 g/dl [HR = 2.4 95% CI (1.3; 4.4); ref at least 12 g/dl], and BMI less than 18 kg/m [HR = 2.1 95% CI (1.3; 3.4); ref = 18-25 kg/m] were associated with higher mortality over the first 24 months. Similar associations were found for LTFU. CONCLUSION: Mortality and LTFU are high among ART-receiving HIV-2-infected individuals and higher in men than in women. There is a critical need to further determine the causes of poor retention and implement sex-specific solutions that improve outcomes in HIV-2 ART programmes.
OBJECTIVES:HIV-2-infected individuals usually initiate antiretroviral therapy (ART) at an advanced age compared with HIV-1patients, with a potential impact on treatment outcomes. This study aimed to investigate the effect of sex and age on mortality and loss to follow-up (LTFU) among HIV-2-infected individuals initiating ART. METHODS: Analyses were conducted using the database of the International Epidemiological Databases to Evaluate AIDS's collaboration in West Africa. LTFU was considered if the interval between the last visit and the closing date for this analysis was more than 180 days. Probability of death and LTFU were estimated with Kaplan-Meier methods. A Cox regression model was used to identify factors associated with death and LTFU over the first 24 months on ART. RESULTS: A total of 1825 HIV-2-infected individuals, including 60% women were considered for this analysis. The median age, baseline CD4 cell count, and follow-up duration were 45 years [interquartile range (IQR; 38-52)], 185 cells/μl [IQR (95-297)], and 28.8 months [IQR (9.8-58.9)], respectively. Over the first 24 months, the mortality rate was 5.2/100 person-years of observation [95% confidence interval (CI; 4.4-6.1)] and 469 (25.7%) were LTFU. Male sex [hazard ratio (HR) = 1.9; 95% CI (1.4; 2.8)], baseline CD4 cell count less than 100 cell/μl [HR = 4.4 95% CI (1.7; 11.1); ref at least 350 cell/μl], haemoglobin 7.5-10 g/dl [HR = 2.4 95% CI (1.3; 4.4); ref at least 12 g/dl], and BMI less than 18 kg/m [HR = 2.1 95% CI (1.3; 3.4); ref = 18-25 kg/m] were associated with higher mortality over the first 24 months. Similar associations were found for LTFU. CONCLUSION: Mortality and LTFU are high among ART-receiving HIV-2-infected individuals and higher in men than in women. There is a critical need to further determine the causes of poor retention and implement sex-specific solutions that improve outcomes in HIV-2ART programmes.
Authors: Claudia Hawkins; Guerino Chalamilla; James Okuma; Donna Spiegelman; Ellen Hertzmark; Eric Aris; Tarcila Ewald; Ferdinand Mugusi; Deo Mtasiwa; Wafaie Fawzi Journal: AIDS Date: 2011-06-01 Impact factor: 4.177
Authors: Sanne Jespersen; Bo Langhoff Hønge; Joakim Esbjörnsson; Candida Medina; David da Silva Té; Faustino Gomes Correira; Alex Lund Laursen; Lars Østergaard; Andreas Andersen; Peter Aaby; Christian Erikstrup; Christian Wejse Journal: Trop Med Int Health Date: 2015-12-21 Impact factor: 2.622
Authors: Boris K Tchounga; Andre Inwoley; Patrick A Coffie; Daouda Minta; Eugene Messou; Guillaume Bado; Albert Minga; Denise Hawerlander; Coumba Kane; Serge P Eholie; François Dabis; Didier K Ekouevi Journal: J Int AIDS Soc Date: 2014-08-11 Impact factor: 5.396
Authors: Katharina Kranzer; Darshini Govindasamy; Nathan Ford; Victoria Johnston; Stephen D Lawn Journal: J Int AIDS Soc Date: 2012-11-19 Impact factor: 5.396
Authors: Alfred Osoti; Tecla M Temu; Nicholas Kirui; Edmond K Ngetich; Jemima H Kamano; Stephanie Page; Carey Farquhar; Gerald S Bloomfield Journal: AIDS Patient Care STDS Date: 2018-06 Impact factor: 5.078
Authors: Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2018-09-24 Impact factor: 5.191
Authors: Dana N Raugi; Selly Ba; Ousseynou Cisse; Khardiata Diallo; Ibrahima Tito Tamba; Cheikh Ndour; Ndeye Mery Dia Badiane; Louise Fortes; Mouhamadou Baïla Diallo; Dominique Faye; Robert A Smith; Fatima Sall; Macoumba Toure; ElHadji Ibrahima Sall; Habibatou Diallo Agne; Khadim Faye; Jean Philippe Diatta; Marie Pierre Sy; Ming Chang; Binetou Diaw; Jacques Sambou; Raphael Bakhoum; Mame Demba Sy; Alassane Niang; Jean Jacques Malomar; Robert W Coombs; Stephen E Hawes; Ibra Ndoye; Nancy B Kiviat; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb Journal: Clin Infect Dis Date: 2021-02-01 Impact factor: 20.999
Authors: Nazik Elmalaika Husain; Sufian K Noor; Wadie M Elmadhoun; Ahmed O Almobarak; Heitham Awadalla; Clare L Woodward; Dushyant Mital; Mohamed H Ahmed Journal: HIV AIDS (Auckl) Date: 2017-11-08
Authors: Selly Ba; Ndeye Mery Dia-Badiane; Stephen Edward Hawes; Louise Fortes Deguenonvo; Fatima Sall; Cheikh Tidiane Ndour; Khadim Faye; Fatou Traoré; Macoumba Touré; Marie Pierre Sy; Dana Noelle Raugi; Nancy Berenice Kiviat; Robert Alexander Smith; Moussa Seydi; Papa Salif Sow; Geoffrey Scott Gottlieb Journal: Pan Afr Med J Date: 2019-07-18
Authors: Frédérique Chammartin; Cam Ha Dao Ostinelli; Kathryn Anastos; Antoine Jaquet; Ellen Brazier; Steven Brown; Francois Dabis; Mary-Ann Davies; Stephany N Duda; Karen Malateste; Denis Nash; Kara Wools-Kaloustian; Per M von Groote; Matthias Egger Journal: BMJ Open Date: 2020-05-15 Impact factor: 2.692